Proceedings of the National Academy of Sciences · 1999 · 383 citations · 39 references
Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyTumor ImmunologyAntigen PresentationAntitumor T Cell ResponsesCancer ImmunotherapyT Cell Responses To TumorsTumor AntigensTumor-associated AntigensIndirect EffectsMhc Class Ii DeficiencyMhc Class Ii MoleculesMhc-peptide RecognitionPeptide EpitopesTumor Antigen RecognitionTumor ImmunogenicityTumor Rejection Antigens
CD4(+) T cells can eliminate tumor cells in vivo in the absence of CD8(+) T cells. We have CD4(+) T cells specific for a MHC class II-restricted, tumor-specific peptide derived from a mutant ribosomal protein expressed by the UV light-induced tumor 6132A-PRO. By using neutralizing mAb specific for murine IFN-gamma and adoptive transfer of CD4(+) T cells into severe combined immunodeficient mice, we show that anti-IFN-gamma treatment abolishes the CD4(+) T cell-mediated rejection of the tumor cells in vivo. The tumor cells were MHC class II negative, and IFN-gamma did not induce MHC class II expression in vitro. Therefore, the tumor-specific antigenic peptide must be presented by host cells and not the tumor cells. Tumor cells transduced to secrete IFN-gamma had a markedly reduced growth rate in severe combined immunodeficient mice, but IFN-gamma did not inhibit the growth of the tumor cells in vitro. Furthermore, tumor cells stably expressing a dominant-negative truncated form of the murine IFN-gamma receptor alpha chain, and therefore insensitive to IFN-gamma, nevertheless were rejected by the adoptively transferred CD4(+) T cells. Thus, host cells, and not tumor cells, seem to be the target of IFN-gamma. Together, these results show that CD4(+) T cells can eliminate IFN-gamma-insensitive, MHC class II-negative cancer cells by an indirect mechanism that depends on IFN-gamma.
39
David E. Hapeman · Technometrics · 1991 · 9.1K citations
Glen Dranoff, Elizabeth M. Jaffee, A Lazenby et al. · Proceedings of the National Academy of Sciences · 1993 · 2.8K citations
Medicine, Immunology, Oncology +17
Joseph L. Fleiss, Alan Agresti · Journal of the American Statistical Association · 1991 · 2.7K citations
Elizabeth Walter, Philip D. Greenberg, M. Jean Gilbert et al. · New England Journal of Medicine · 1995 · 1.8K citations
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Kenneth E. Hung, Robert J. Hayashi, Anne Lafond-Walker et al. · The Journal of Experimental Medicine · 1998 · 1.3K citations · Full text
Life Sciences, Immunology, Oncology +17